Operating
Increase (Decrease) in Prepaid Expense and Other Assets
Regeneron Pharmaceuticals Increase (Decrease) in Prepaid Expense and Other Assets increased by 314.6% to $198.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.6%, from $179.50M to $198.60M.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026Apr 29, 2026
How to read this metric
An increase represents a cash outflow for future benefits, while a decrease represents the realization of previously paid expenses, effectively freeing up cash flow.
Detailed definition
This tracks changes in prepayments for goods or services that will be consumed in future periods. An increase in these a...
Peer comparison
Standard working capital metric; peers will show similar fluctuations based on their procurement and service contract cycles.
Metric ID:
operating_increase_decrease_in_prepaid_deferred_expense__313362Historical Data
16 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $227.80M | $39.00M | $44.80M | $243.70M | -$121.20M | $5.50M | $3.40M | $275.50M | $77.90M | $526.30M | -$252.00M | $55.30M | $179.50M | $230.70M | $47.90M | $198.60M |
| QoQ Change | — | -82.9% | +14.9% | +444.0% | -149.7% | +104.5% | -38.2% | >999% | -71.7% | +575.6% | -147.9% | +121.9% | +224.6% | +28.5% | -79.2% | +314.6% |
| YoY Change | — | — | — | +7.0% | -410.8% | -87.7% | -98.6% | +327.3% | >999% | >999% | -191.5% | — | +130.4% | -56.2% | +119.0% | +10.6% |
Range-$252.00M – $526.30M
CAGR-3.6%
Avg YoY Growth>999%
Median YoY Growth+8.8%
Increase (Decrease) in Prepaid Expense and Other Assets at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's increase (decrease) in prepaid expense and other assets?
- Regeneron Pharmaceuticals (REGN) reported increase (decrease) in prepaid expense and other assets of $198.60M in Q1 2026.
- How has Regeneron Pharmaceuticals's increase (decrease) in prepaid expense and other assets changed year-over-year?
- Regeneron Pharmaceuticals's increase (decrease) in prepaid expense and other assets increased by 10.6% year-over-year, from $179.50M to $198.60M.
- What does increase (decrease) in prepaid expense and other assets mean?
- The net change in cash spent on expenses paid in advance.